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Introduction:Molecular radiotherapy exploiting short-range Auger electron-emitting radionuclides has potential
for targeted cancer treatment and, in particular, is an attractive option for managing micrometastatic disease.
Here, an approach using chelator-trastuzumab conjugates to target radioactivity to breast cancer cells was eval-
uated as a proof-of-concept to assess the suitability of 67Ga as a therapeutic radionuclide.
Methods: THP-trastuzumab and DOTA-trastuzumab were synthesised and radiolabelled with Auger electron-
emitters 67Ga and 111In, respectively. Radiopharmaceuticals were tested for HER2-specific binding and
internalisation, and their effects on viability (dye exclusion) and clonogenicity of HER2-positive HCC1954 and
HER2–negative MDA-MB-231 cell lines was measured. Labelled cell populations were studied by
microautoradiography.
Results: Labelling efficiencies for [67Ga]Ga-THP-trastuzumab and [111In]In-DOTA-trastuzumabwere 90% and 98%,
respectively, giving specific activities 0.52 ± 0.16 and 0.61 ± 0.11 MBq/μg (78–92 GBq/μmol). At 4 nM total an-
tibody concentration and 200 × 103 cells/mL, [67Ga]Ga-THP-trastuzumab showed higher percentage of cell asso-
ciation (10.7 ± 1.3%) than [111In]In-DOTA-trastuzumab (6.2± 1.6%; p=0.01). The proportion of bound activity
that was internalised did not differ significantly for the two tracers (62.1 ± 1.4% and 60.8± 15.5%, respectively).
At 100 nM, percentage cell binding of both radiopharmaceuticals was greatly reduced compared to 4 nM and did
not differ significantly between the two (1.2 ± 1.0% [67Ga]Ga-THP-trastuzumab and 0.8 ± 0.9% for [111In]In-
DOTA-trastuzumab). Viability and clonogenicity of HER2-positive cells decreased when each radionuclide was
incorporated into cells by conjugation with trastuzumab, but not when the same level of radioactivity was con-
fined to the medium by omitting the antibody conjugation, suggesting that 67Ga needs to be cell-bound or
internalised for a therapeutic effect. Microautoradiography showed that radioactivity bound to individual cells
varied considerably within the population.
Conclusions: [67Ga]Ga-THP-trastuzumab reduced cell viability and clonogenicity only when cell-bound, suggest-
ing 67Ga holds promise as a therapeutic radionuclide as part of a targeted radiopharmaceutical. The causes and
consequences of non-homogeneous uptake among the cell population should be explored.
© 2019 . Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
With regulatory approval of beta particle-emitting radiopharmaceu-
ticals such as [177Lu]Lu-DOTATATE [1], early successes in trials of alpha
particle-emitting therapy 223Ra [2] and an increasing choice of thera-
peutic radionuclides, chelators and radiochemistry techniques to
choose from, this is an exciting time for molecular radiotherapy. Exam-
ples of therapeutic radiopharmaceuticals in routine clinical use include
131I for thyroid cancer, [131I]mIBG for neuroblastoma, 90Y- and 177Lu-artment of Imaging Chemistry
g Sciences, 4th floor Lambeth
om.
).
pen access article under the CC BY li
rger, I. Costa, et al., In vitro cy
6/j.nucmedbio.2019.12.004radiopeptides for neuroendocrine tumours, and 90Y-labelled micro-
spheres (albeit defined for regulatory purposes as a medical device
rather than a radiopharmaceutical) for hepatic tumours [3,4]. Most
prominent amongnewbeta particle-emitting radiopharmaceuticals un-
dergoing clinical trials is [177Lu]Lu-PSMA [5]. The potential of high linear
energy transfer alpha particle-emitters, such as 213Bi, 225Ac, 211At, and
227Th [6–8] to treat low volume tumours effectively while limiting
healthy tissue toxicity is being explored. By comparison with alpha
particles (b100 μm particle range), the short range (often b1 μm) of
Auger electrons and related secondary electrons would be expected to
increase the therapeutic ratio and further mitigate non-target toxicity
[9]. Although likely to be less effective than beta emitters in large
tumours because of the lack of “cross-fire” contribution to the tumour
radiation dose, Auger electron-emitters could be effective against single
cells and micrometastases which are ineffectively treated by beta-cense (http://creativecommons.org/licenses/by/4.0/).
totoxicity of Auger electron-emitting [67Ga]Ga-trastuzumab, Nuclear
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[11,12].
Among therapeutic Auger electron-emitters, 111In has so far been
closest to clinical translation and has been evaluated in both breast
cancer [13] and neuroendocrine tumours [14]. 67Ga, which has
been used clinically for SPECT imaging of inflammation and infection
[15,16] also emits Auger electrons but its use as a therapeutic radio-
nuclide is relatively unexplored [17–22]. Despite promising in vitro
results, including its use in a radiopharmaceutical targeted towards
the CD74 receptor on human B-lymphoma cells [21,22], low specific
activities and a lack of purpose-designed gallium chelators have hin-
dered progress with 67Ga therapy. The recent development of sev-
eral new chelators [23–30], including the tris(hydroxypyridinone)
chelators, allow kit-based radiolabelling of biomolecules, including
proteins, with gallium radionuclides at high specific activities
[31–33]. This development provides renewed opportunities for clin-
ical translation to assess the tumouricidal potential of 67Ga preclini-
cally and clinically as a radionuclide for molecular radionuclide
therapy. Our recent studies have shown that 67Ga caused more
DNA damage per Bq than 111In in a cell-free system. The cellular ra-
dioactivity required to kill 50% and 90% of HCC1954 breast cancer
cells was 6- and 1.5-fold less, respectively, for 67Ga than for 111In
[9,34]. Lower plasmid DNA damage was caused by 67Ga than 111In
when the radionuclides were physically separated from the DNA,
suggesting that 67Ga would cause less unwanted damage to sur-
rounding non-target cells than 111In [34]. These data suggest that
67Ga could be selectively cytotoxic if targeted to tumour cells, with
minimal damage to nearby non-targeted cells.
A widely explored tumour-specific molecular target is HER2, a re-
ceptor expressed on breast cancer cells. The antibody trastuzumab
binds to HER2 and so is a potential basis for targeted delivery of radio-
nuclides and evaluation of the therapeutic potential of 67Ga. Even in pa-
tients with primary tumours classified as HER2-negative, their
metastases can still prove HER2-positive [35]. HER2-positivity in pa-
tients with breast cancer is associated with aggressive disease, poor
prognosis and shortened overall survival [36]. A combination of
trastuzumab, pertuzumab and docetaxel was able to partially overcome
trastuzumab resistance and extend survival of patients with metastatic
HER2-positive breast cancer from 15 (trastuzumab alone) to
56.5 months [37]. This drug combination is now used as first-line ther-
apy for metastatic HER2-positive breast cancer. Another successful ap-
proach uses antibody-drug conjugates, such as the trastuzumab
conjugate T-DM1, which delivers a toxic payload of emtansine to
HER2-positive breast cancer cells [38]. The success of T-DM1 suggests
that the efficacy of using a radionuclide, such as an Auger electron-
emitter, as the toxic payload, should be explored [38]. In this study,
trastuzumab was used to target 67Ga to HER2-positive breast cancer
cells to determine the ability of 67Ga to kill these cells selectively com-
pared to [111In]In-DOTA-trastuzumab.2. Materials and methods
2.1. Radionuclide preparation
Radiolabelling was carried out with 67Ga used either as supplied
([67Ga]Ga-citrate at a concentration of 80–160 MBq in 2.2 mL;
Mallinckrodt, Netherlands) or after converting to [67Ga]GaCl3 as
previously described [39]. For conversion to [67Ga]GaCl3, [67Ga]Ga-
citrate was diluted to 5 mL with distilled water and concentrated
on a SEP-PAK silica light 120 mg column (Waters, USA) at 1 mL/
min. Trapped 67Ga was eluted with 0.1 M HCl in 50 μL fractions.
The radioactivity concentration in the highest fraction (usually frac-
tion 6 or 7) was 1010 ± 388 MBq/mL [111In]InCl3 (110–200 MBq)
was used as supplied in 0.3 mL hydrochloric acid (Mallinckrodt,
Netherlands).Please cite this article as: M.F. Othman, E. Verger, I. Costa, et al., In vitro cy
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Trastuzumab was conjugated to chelators tris(hydroxypyridinone)
(H3-THP-Ph-SCN; THP, synthesised as previously described [40]) and
S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane
tetraacetic acid (p-SCN-Bn-DOTA, Macrocyclics, USA; DOTA) for
radiolabelling with 67Ga and 111In, respectively.
2.2.1. THP-trastuzumab
Trastuzumab (435 μL, 22.96 mg/mL) in physiological saline was in-
cubatedwith 50mMethylenediaminetetraacetate sodium (EDTA) solu-
tion for 30min to remove any adventitious metal ions. Themixture was
filtered at 4000 g in a Vivaspin 2 filter (Sartorius, Germany). The filter
was washed with metal-free HEPES and the antibody thus recovered
had a concentration of 12.46± 0.05mg/mL (as measured by NanoDrop
spectrophotometer) in metal-free HEPES. This solution of trastuzumab
(3.23 mg, 260 μL, pH 8.7) was incubated with THP (21 μL of 10 mM so-
lution in DMSO) at 10:1 chelator:antibody molar ratio at room temper-
ature (2 h) and then 4 °C (2 h). The mixture was applied to a Sephadex
PD MidiTrap G-25 size exclusion column (GE Healthcare) and eluted
with 0.2 M ammonium acetate. The fraction eluting between 1 mL and
2.5 mL was applied to a Sephadex PD-10 size exclusion column (GE
Healthcare), and eluted with 0.2 M ammonium acetate solution in
500 μL fractions. Fraction 8 (protein concentration 3.5mg/mL,measured
by NanoDrop) was used for radiolabelling.
2.2.2. DOTA-trastuzumab
850 μL trastuzumab (23.5 mg/mL in saline) was dialysed overnight
in a 3.5 kDa MWCO Slide-a-lyzer™ cassette (ThermoFisher, USA)
against 0.2 M, pH 5.5 sodium acetate containing 2 g/L chelex (Sigma,
UK). DOTA conjugation to trastuzumab (10 mg, 12.8 mg/mL) was
achieved by incubating a reaction solution containing a 40:1 M ratio of
chelator to antibody, i.e. 1.1 mg DOTA (p-SCN-Bn-DOTA, Macrocyclics,
USA; 110 mg/mL in 0.25 M pH 5.5 sodium acetate) to which 83 μL 1 M
NaHCO3, pH 9.5 was added and the mixture stirred for 60 min at room
temperature. The conjugated antibody was dialysed against 0.2 M,
pH 5.5 ammonium acetate containing 2 g/L chelex to remove unbound
p-SCN-Bn-DOTA, furnishing a 13.5 mg/mL DOTA-trastuzumab solution
(measured by NanoDrop).
2.3. Radiolabelling and quality control
2.3.1. [67Ga]Ga-THP-trastuzumab
[67Ga]Ga-citrate (48.6 MBq/mL) was added as aliquots of 25 μL
(1.2 MBq), 100 μL (4.9 MBq) and 200 μL (9.7 MBq) to 100 μg THP-
trastuzumab in 0.2M ammoniumacetate (3.5mg/mL). pHwas adjusted
to 6.5 with 0.1MNaHCO3. Themixturewas left for 15min at room tem-
perature. Unchelated 67Gawas scavengedwith 2 μL 50mMEDTA. Alter-
natively, [67Ga]GaCl3 (58.3 ± 11.9 MBq in 80 μL) was added to 100 μg
THP-trastuzumab in 0.2M ammonium acetate (3.5mg/mL), pHwas ad-
justed to 6.5 with 0.1 M NaHCO3 and the mixture was left for 15 min at
room temperature.
2.3.2. [111In]In-DOTA-trastuzumab
[111In]InCl3 (94.1 ± 29.4 MBq in 120 ± 30 μL) was mixed with
250–430 μL 0.1 M ammonium acetate, pH 5.5, and added to 150 μg
DOTA-trastuzumab. The mixture was kept at 40 °C for 2 h. Unchelated
111In was scavenged with 2 μL of 50 mM EDTA.
2.3.3. Quality control
Labelling efficiencies were determined by paper chromatography on
Whatman 1 paper (1 cm × 6.5 cm) with a mobile phase of 1 mMDTPA
and were almost always N95%. Preparations in which the radiochemical
puritywas ≤95%were purified using a PD-10 column in 1mL fractions of
PBS containing 0.1% BSA.totoxicity of Auger electron-emitting [67Ga]Ga-trastuzumab, Nuclear
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MDA-MB-231 (HER2-negative) and HCC1954 (HER2-positive)
breast cancer cell lines were grown as monolayers at 37 °C in a humid-
ified atmosphere with 5% CO2 in high glucose (4.5 g/L) Dulbecco's Mod-
ified Eagle Medium (DMEM; PAA Laboratories) and RPMI-1640,
respectively. Media were supplemented with 1.5 mM L-glutamine
(PAA Laboratories, Austria), 10% foetal bovine serum (Invitrogen) and
penicillin/streptomycin (Invitrogen) to create full medium. Cells were
harvested using trypsin-EDTA for experimental use.
2.5. Binding assay
5 × 104 HCC1954 cells per well were seeded in a 6-well plate 24 h
prior to the experiment and incubated in a 5% CO2 incubator at 37 °C.
4 nM [67Ga]Ga-THP-trastuzumab or [111In]In-DOTA-trastuzumab (0.08
and 0.09 MBq, respectively) were added to cells in a final volume of
250 μL full medium followed by incubation for 1 h at 37 °C. Medium
was collected and combined with supernatant from two subsequent
PBS wash steps to measure unbound activity. Cells were lysed in their
wells with 1 mL 0.1 M NaOH and the solutions transferred to counting
tubes to measure bound activity. Radioactivity was measured with a
Wallac 1282 Compugamma gamma counter (Wallac, Germany) to cal-
culate the percentage of cell-bound radioactivity. Controls included
non-internalised activity (antibody-free [67Ga]Ga-THP and [111In]In-
DOTA; 0.5 MBq) in HCC1954 cells, and HER2-negative MDA-MB-231
cells incubated with 4 nM [67Ga]Ga-THP-trastuzumab or [111In]In-
DOTA-trastuzumab.
2.6. Internalisation assay
1 × 106 HCC1954 cells in suspension were incubated with 4 nM
[67Ga]Ga-THP-trastuzumab or [111In]In-DOTA-trastuzumab (0.08 and
0.09MBq, respectively) in 1mLmedium for 1 h at 37 °C. Unbound activ-
ity in themediumwas collected and combinedwithwashings from two
PBS wash steps after centrifuging at 1500 rpm for 5 min. Cell pellets
were subjected to an acid wash by resuspending in 1 mL 500 mM
NaCl and 200 mM NaOAc (pH 2.5) for 5 min at 4 °C [41]. Cells were
then centrifuged to separate membrane-associated activity (superna-
tant) from internalised activity (pellet). Radioactivity was measured as
above.
2.7. Viability
[67Ga]Ga-THP-trastuzumab or [111In]In-DOTA-trastuzumab
(0.18 MBq/μg, 27 GBq/μmol) was added to 50 × 103 HCC1954 cells in
250 μL full medium per well at 0, 4, 10, 40 and 100 nM, i.e. 0, 0.02,
0.06, 0.2 and 0.6 MBq, respectively, per well. Controls included un-
treated HCC1954 cells, HCC1954 cells incubated with 100 nM non-
radiolabelled trastuzumab, non-cell-binding activity ([67Ga]Ga-THP
and [111In]In-DOTA; 0.5 MBq), and MDA-MB-231 cells incubated with
100 nM [67Ga]Ga-THP-trastuzumab or [111In]In-DOTA-trastuzumab.
Following a one-hour incubation, the supernatant was removed and
cells were washed in PBS and resuspended in 2 mL full medium. Viabil-
ity was measured after 3 days incubation in the 5% CO2 incubator at
37 °C using the trypan blue exclusion assay. Viability values were nor-
malised to the untreated group (set at 100%).
2.8. Clonogenic assay
2 × 103 cells per well were plated in 6-well plates 24 h prior to the
experiment. HCC1954 cells were incubated with 0.18 MBq/μg
(27 GBq/μmol) radiolabelled trastuzumab in 500 μL for 1 h at 37 °C.
The radioactive supernatant was then removed and cells were incu-
bated in 2 mL full medium in a 5% CO2 incubator at 37 °C. The medium
was changed every 3 days. After 9–14 days, cells were fixed and stainedPlease cite this article as: M.F. Othman, E. Verger, I. Costa, et al., In vitro cy
Medicine and Biology, https://doi.org/10.1016/j.nucmedbio.2019.12.004with 1:1 methanol/1% crystal violet (Sigma, UK). Surviving fractions
were calculated by counting colonies consisting of N50 cells. Controls in-
cluded HCC1954 cells incubated with 100 nM non-radiolabelled
trastuzumab, non-cell-binding radiopharmaceutical ([67Ga]Ga-THP
and [111In]In-DOTA; at 1 MBq) and MDA-MB-231 cells incubated with
100 nM [67Ga]Ga-THP-trastuzumab or [111In]In-DOTA-trastuzumab.
Clonogenic survival values were normalised to the untreated group
(set at 1.0).2.9. Microautoradiography
1 × 106 HCC1954 cells in suspension were treated with 0 or 4 nM
[67Ga]Ga-THP-trastuzumab (0 and 0.04 MBq, respectively; 0.07 MBq/
μg, 11 GBq/μmol) in 1 mL full medium. Preparations were incubated in
a 5% CO2 incubator at 37 °C for 1 h and washed in PBS, fixed in 4% form-
aldehyde in PBS for 20 min at room temperature, washed and re-
suspended in 200 μL PBS. Gelatine was dissolved in PBS in a microwave
oven. Once cooled to about 37 °C, 400 μL of the 18% gelatin solutionwas
added to cells (200 μL PBS) in a 1 cm × 1 cmmould and kept at 4 °C for
15min. Once solidified, the gelatine blockwas trimmed to into cubes of
4 × 4 × 4mm, whichwere snap frozen in isopentane in liquid nitrogen.
Sections 10 μm thick were cut in a cryotome (Bright Instrument Com-
pany Ltd., UK) and placed on positively-charged polylysine-coated
slides. In a dark room, the slides were coated by dipping in K2 Ilford
photographic emulsion (Ilford, Germany), which was prepared by
adding10mLemulsion to 16.7mLdistilledwater containing 0.01% glyc-
erol and gently heating to 37 °C until dissolved. Dipped slides were left
to dry horizontally at 4 °C for 24 h in a light-protected case, and devel-
oped at room temperature for 5 min in Kodak D19 (Kodak, USA; 15.8%
(w/v) in distilled water). Slides were then dipped in 1% acetic acid for
30 s and then in 0.5% gelatin and dried at room temperature. Finally, au-
toradiographs were fixed in 30% sodium thiosulfate for 5 min, washed
for 10 min and left to dry. Prior to imaging, 50 μL DAPI-containing
mounting solution was applied to the slide and a coverslip was placed
on top. Images were acquired with an EVOS FL Cell imagingmicroscope
(Life Technologies, USA) and analysed with Image J (NIH, USA). The
total number of silver grains around each cell was measured (within a
circle 25 μm in diameter around the cell centre) in cells identified as
DAPI-positive. The amount of signal in cells was corrected for back-
ground in an equivalent cell-free area of the image.2.10. Statistical analysis
Statistical analysis was performed using Graphpad Prism Version
7.0c. An unpaired two-tailed t-testwas used to analyse binding assay re-
sults comparing [67Ga]Ga-THP-trastuzumab uptake with [111In]In-
DOTA-trastuzumab. A one-sample two-tailed t-test and a paired two-
tailed t-test were used to analyse viability and survival fraction data.
Data, except Fig. 1B, are average ± standard deviation.3. Results
3.1. Radiolabelling
The labelling efficiencies for THP-trastuzumab labelling with [67Ga]
Ga-citrate were 100%, 84% and 33% for 25 μL (1.2 MBq), 100 μL
(4.9 MBq), and 200 μL (9.7 MBq), respectively. This led to low specific
activities of between 0.01 and 0.04 MBq/μg (2–6 GBq/μmol). However,
radiolabelling THP-trastuzumab with [67Ga]GaCl3 achieved N90% radio-
chemical yield and a specific activity of 0.52 ± 0.16 MBq/μg (78 GBq/
μmol). [67Ga]GaCl3 was therefore used for all further radiolabellings.
[111In]In-DOTA-trastuzumab gave a radiolabelling yield of 98% with
specific activity of 0.61 ± 0.11 MBq/μg (92 GBq/μmol).totoxicity of Auger electron-emitting [67Ga]Ga-trastuzumab, Nuclear
Fig. 1. A. Binding of [67Ga]Ga-THP-trastuzumab and [111In]In-DOTA-trastuzumab to
50 × 103 HER2-positive HCC1954 cells at increasing trastuzumab concentrations (n =
3). B. Calculated mean activity per HCC1954 HER2-positive cell (Bq/cell) for [67Ga]Ga-
THP-trastuzumab and [111In]In-DOTA-trastuzumab. C. Binding of [67Ga]Ga-THP-
trastuzumab and [111In]In-DOTA-trastuzumab to HCC1954 cells at 4 and 100 nM.
Controls include non-internalised activity ([67Ga]Ga-THP and [111In]In-DOTA; 0.5 MBq)
and HER2-negative MDA-MB-231 incubated with 4 nM [67Ga]Ga-THP-trastuzumab and
[111In]In-DOTA-trastuzumab (control cells) (n = 3).
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Both [67Ga]Ga-THP-trastuzumab (0.52 ± 0.16 MBq/μg) and [111In]
In-DOTA-trastuzumab (0.61 ± 0.11 MBq/μg) specifically bound to
HER2-positive HCC1954 cells. At 4 nM total antibody concentration,
[67Ga]Ga-THP-trastuzumab showed higher binding (10.7 ± 1.3%) than
[111In]In-DOTA-trastuzumab (6.2 ± 1.6%; p = .02; 50 × 103 cells,
Fig. 1A). The percentage binding of both preparations decreased with
increasing trastuzumab concentration. On increasing total antibody
concentration to 100 nM, binding of [67Ga]Ga-THP-trastuzumab and
[111In]In-DOTA-trastuzumab was inhibited and reduced to 1.2 ± 1.0%
and 0.8 ± 0.9% (p= 0.85), respectively, indicating target-specific bind-
ing. However, the total activity bound to cells was higher at the highest
antibody concentrations (Fig. 1B). Binding of antibody-free [67Ga]Ga-
THP and [111In]In-DOTA to HCC1954 cells was minimal (0.07 ± 0.02%
and 0.03 ± 0.00%, respectively). Binding of [67Ga]Ga-THP-trastuzumab
and [111In]In-DOTA-trastuzumab to HER2-negative MDA-MB-231 cells
was 0.18 ± 0.10% and 0.21 ± 0.23%, respectively, again confirming
that binding was HER2-specific.
Binding of 4 nM [67Ga]Ga-THP-trastuzumab or [111In]In-DOTA-
trastuzumab to 1 × 106 HCC1954 cells (19.71 ± 1.32% and 11.93 ±
3.32%, respectively) was higher than to 5 × 104 cells (10.7 ± 1.3% and
6.2 ± 1.6%, respectively). Of the cell-bound fraction, 62.1 ± 1.4% and
60.8 ± 15.5% was internalised for [67Ga]Ga-THP-trastuzumab and
[111In]In-DOTA-trastuzumab, respectively.Please cite this article as: M.F. Othman, E. Verger, I. Costa, et al., In vitro cy
Medicine and Biology, https://doi.org/10.1016/j.nucmedbio.2019.12.0044. Viability (trypan blue staining)
Treatment of HER2-positive HCC1954 cells with 100 nM non-
radiolabelled trastuzumab did not affect viability (relative viability
101 ± 3.7% compared to untreated control cells whose relative viability
was defined as 100%). Following treatment of HER2-positive HCC1954
cells with either [67Ga]Ga-THP-trastuzumab or [111In]In-DOTA-
trastuzumab, their viability, as measured with trypan blue staining, de-
creased as the [67Ga]Ga-THP-trastuzumab concentration and the activ-
ity added to the medium (and hence the cell-bound activity per cell)
increased (Fig. 2A, B). Treatment of HCC1954 cells with [67Ga]Ga-THP-
trastuzumab at 100 nM(2MBq/mL) gave an average cellular radioactiv-
ity of 0.14 Bq/cell and produced significant reduction in cell viability (to
66.5 ± 4.8% of the control value which was defined as 100 ± 8.6% at
0 nM antibody concentration, p = 0.007) (Fig. 2A–C). Under the same
conditions, [111In]In-DOTA-trastuzumab, gave an average cellular up-
take of 0.10 Bq/cell, and reduced viability to 66.2 ± 6.7% of the control
value. Thus, the effect of the two radiopharmaceuticals (at similar aver-
age cell-bound activity per cell) on viability was not significantly differ-
ent (p N 0.9). Treatment of HER2-positive cells with non-antibody-
conjugated [67Ga]Ga-THP (which did not bind to cells) did not measur-
ably reduce cell viability, while non-antibody-conjugated [111In]In-
DOTA (which also was not cell-bound)marginally decreased cell viabil-
ity to 85.2± 4.0% of the control (Fig. 2D). Thus, both radionuclideswere
significantly less toxic to HER2-positive HCC1954 cells when not cell-
bound (p = 0.0003 for 67Ga and p = 0.0146 for 111In). The difference
in toxicity of non-cell-bound 67Ga and 111In was not significant (p =
0.09). The results suggest that 67Ga and 111In need to be bound to
cells to achieve significant reduction in cell viability.
4.1. Clonogenicity
Treatment of HER2-positive HCC1954 cells with 100 nM non-
radiolabelled trastuzumab did not affect clonogenicity (relative
clonogenicity 0.97 ± 0.13 compared to untreated control cells whose
relative clonogenicity was defined as 1.0). Treatment with either
[67Ga]Ga-THP-trastuzumab or [111In]In-DOTA-trastuzumab decreased
their relative clonogenicity as concentration of radiolabelled
trastuzumab, and consequently the amount of activity per cell, in-
creased (Fig. 3A–C). Treatment of HCC1954 cells with 100 nM [67Ga]
Ga-THP-trastuzumab and [111In]In-DOTA-trastuzumab reduced the
clonogenic fraction to 0.43 ± 0.04 and 0.60 ± 0.07, respectively, com-
pared to the untreated control (1.0 ± 0.18; p= 0.002 and 0.01, respec-
tively). The effect of [67Ga]Ga on clonogenicity, at similar average
activity per cell, was significantly greater than that of 111In (p = 0.01).
Treatment of HER2-positive cells with non-antibody-conjugated (and
hence non-internalised) [67Ga]Ga-THP or [111In]In-DOTA reduced
clonogenicity only marginally (0.88 ± 0.08, p = 0.13 and 0.82 ± 0.09,
p = 0.04, respectively) compared to untreated control HCC1954 cells
(Fig. 3D). The difference between clonogenic fraction of cells treated
with 100 nM [67Ga]Ga-THP-trastuzumab (0.43 ± 0.04) and [111In]In-
DOTA-trastuzumab and (0.60± 0.07) and non-cell-bound radioactivity
(0.88 ± 0.08 and 0.82 ± 0.09 for [67Ga]Ga and [111In]In, respectively)
was also significant (p= .01 and 0.05, respectively). Clonogenic survival
was significantly impaired by treatment with [67Ga]Ga-THP-
trastuzumab even at very low average activity per cell (b0.05 Bq/cell)
but the effect of increasing the activity per cell beyond this level was
less dramatic additional effect (Fig. 3B, C).
5. Microautoradiography
Of the activity added in this experiment (0.04 MBq, 0.07 MBq/μg,
11 GBq/μmol), 14.86 ± 0.38% of [67Ga]Ga-THP-trastuzumab was
cell-bound. Microautoradiography revealed that radioactivity at-
tached to individual cells varied considerably among the cell popula-
tion; 15% of cells were classified as unlabelled (≤1 silver grain pertotoxicity of Auger electron-emitting [67Ga]Ga-trastuzumab, Nuclear
Fig. 2. Viability assay (n = 3) using trypan blue 3 days after a one-hour incubation of [67Ga]Ga-THP-trastuzumab or [111In]In-DOTA-trastuzumab with HER2-positive HCC1954 cells at
0.18 MBq/μg over a range of concentrations (A), activity per mL during incubation (B), and activity bound per cell (C). Controls for the viability assay in D are non-internalised activity
in HER2-positive HCC1954 cells incubated with ([67Ga]Ga-THP and [111In]In-DOTA; 0.5 MBq, 2 MBq/mL), HER2-negative MDA-MB-231 cells incubated with 100 nM radiolabelled
trastuzumab, and HER2-positive HCC1954 cells incubated with 100 nM non-radiolabelled trastuzumab (n = 6). (For interpretation of the references to color in this figure legend, the
reader is referred to the web version of this article.)
Fig. 3. Clonogenic assay (n = 3) of HER2-positive HCC1954 cells incubated for 1 h with [67Ga]Ga-THP-trastuzumab or [111In]In-DOTA-trastuzumab at 0.18 MBq/μg over a range of
concentrations (A), activity per mL during incubation (B), and activity bound per cell (C). In D, controls non-internalised activity in HER2-positive HCC1954 cells incubated ([67Ga]Ga-
THP and [111In]In-DOTA; 1 MBq, 2 MBq/mL), HER2-negative MDA-MB-231 cells incubated with 100 nM radiolabelled trastuzumab, and HER2-positive HCC1954 cells incubated with
100 nM non-radiolabelled trastuzumab (n = 6).
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grains per cell, e.g. Fig. 4B), 25% medium labelling (41–90 silver
grains per cell, e.g. Fig. 4C) and 20% high labelling (≥91 per cell, e.g.
Fig. 4D).6. Discussion
This study extends our previous cell-free system studies using
pBR322 plasmids and cells non-specifically labelled using [67Ga]Ga-
oxine, which showed that 67Ga causesmore DNA damage, and a greater
decrease in cancer cell clonogenicitywhen bound to cells, than the same
activity of 111In [34]. Here, we have exploited the targeted delivery of ra-
dionuclides to HER2-positive cells using the antibody trastuzumab to
investigate the selectivity and cytoxicity of targeted radionuclide ther-
apy with 67Ga compared to 111In [10,42–44].
Initial binding studies were carried out to determine the selectivity
of uptake and the concentrations of radiolabelled antibodies required
to achieve sufficient uptake of radionuclide in cells to affect measurable
impact on cell viability and clonogenicity.
Due to difficulty experienced in radiolabelling trastuzumab with
67Ga to a sufficiently high specific activity (i.e. comparable to that
achievable with 111In) under mild conditions using the DOTA chelators,
we used the gallium-specific chelator THP, which can be radiolabelled
with gallium radionuclides in under 5 min, at pH 6.5 and room temper-
ature [23] allowing mild and efficient radiolabelling of proteins [33].
Similar specific activities of 0.52–0.61 MBq/μg (78–92 GBq/μmol)
could thus be achieved for both [67Ga]Ga-THP-trastuzumab and [111In]
In-DOTA-trastuzumab.
At both low and high concentrations of radiolabelled trastuzumab,
the percent binding of [67Ga]Ga-THP-trastuzumab to HER2-positive
HCC1954 cells was somewhat higher (about 1.5 to 1.7-fold) than that
of [111In]In-DOTA-trastuzumab. The choice of radionuclide did not af-
fect the fraction of cell-bound radioactivity that was internalisedwithin
the cell (as opposed to bound to the cell surface), with over 60% of cell-
bound radioactivity being internalised in both cases.
Viability studies using trypan blue staining showed that 67Ga in-
duced significant toxicity, but only if incorporated into the cell; at simi-
lar concentrations in the media, non-antibody-conjugated [67Ga]Ga-Fig. 4. Examples of microautoradiography of HCC1954 cells incubated with 4 nM 67Ga-
THP-trastuzumab showing mostly highly variable activity per cell ranging from very low
(A) to very high (D). The green arrows show the cell boundaries as determined by light
microscopy (green circles) with DAPI staining delineating the nucleus (blue). Silver
grains are red in the images. Scale bar is 100 μm. (For interpretation of the references to
color in this figure legend, the reader is referred to the web version of this article.)
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DOTA, which did not bind to cells, diminished cell viability only slightly,
possibly due to a higher fraction of radiation dose coming from gamma
emissions in the case of 111In. This is consistentwith our previous obser-
vations [34].
Both [67Ga]Ga-THP-trastuzumab and [111In]In-DOTA-trastuzumab
at 100 nM (2.5 MBq/mL) decreased clonogenic survival significantly
compared to untreated HCC1954 cells and compared to HCC1954 cells
incubated with 100 nM non-radiolabelled trastuzumab (Fig. 3), sug-
gesting that themechanism of cell death is mediated by radiation dam-
age. Interestingly, the trends seen in Fig. 3A–C match what one might
expect for a survival curve of tumour cells affected through the by-
stander response [45]. However, further studies will need to be carried
out to determine whether the bystander response is indeed activated
by these Auger-emitting radiopharmaceuticals. Our data using 100 nM
non-radiolabelled trastuzumab (14 μg/mL, 1 h incubation) are in agree-
ment with previous findings that trastuzumab induces no change in
viability of HCC1954 cells even after 7 days of incubation at 15 μg/mL
[46].
At similar radioactivity concentrations in the medium, [67Ga]Ga-
THP-trastuzumab is 1.4-fold more toxic (measured as effect on
clonogenicity) than [111In]In-DOTA-trastuzumab (Fig. 3, A and B). It is
likely that only part of this apparent difference in toxicity is associated
with the 1.5–1.75-fold more activity of [67Ga]Ga-THP-trastuzumab
taken up per cell, because when clonogenicity is plotted against the
measured average activity per cell (Fig. 3, C), 67Ga still shows signifi-
cantly greater suppression of clonogenicity than 111In.
The differences in toxic effects asmeasured by viability (trypanblue)
and clonogenicity indicate that viability and clonogenic assays measure
different aspects of cytotoxicity and are complementary rather than al-
ternative methods.
The modest difference in toxicological profile between the two
radioimmunoconjugates could originate from differences in the cellular
trafficking, or from differences in the electron and photon emission
spectra of the two radionuclides. The 67Ga conjugate shows greater ap-
parent affinity and uptake than the 111In conjugate, and although this
does not cause any significant difference in the measured internalised
fraction, it implies that differences in subsequent intracellular traffick-
ing, including to the cell nucleus, cannot be excluded. Electron emis-
sions (Auger and Coster-Kronig electrons) of 67Ga and 111In are
similar in total energy (6.24 MeV and 6.75 MeV, respectively) and
both also emit internal conversion electrons (0.32 and 0.16 per decay
respectively, with a total energy of 28.078 KeV and 25.957 KeV, respec-
tively). However, the energy distribution, and hence range in tissue, of
the Auger and Coster-Kronig electrons differ markedly between the
two radionuclides. The Supplementary information provides relevant
data in the form of plots of yield of electrons per decay against the log-
arithm of the range [47]. The total energy of the Auger and Coster-
Kronig emissions of 67Ga is distributed among fewer electrons than is
the case for 111In (4.7 and 14.7, respectively [47]) and consequently,
electrons from 67Ga have higher energy per electron, and hence longer
range. Fewer Auger electrons emissions per decay than 14.7 [47] have
been estimated for 111In, namely between 5.84 and 7.43, however
these values are still higher than for 67Ga (between 4.56 and 4.96)
[48]. 67Ga emits no electrons with a range below 1 nm, whereas 111In
emits 8; and 67Ga emits around 0.6 electrons per decay with a range
encompassing multiple compartments of the cell (1–10 μm), whereas
111In emits none. Thus, 111In decay is likely to be biologically effective
over a much smaller range (b1 μm) than 67Ga decay, and the biological
effects of decay of 111In are likely to be much more dependent on its
sub-cellular location than those of 67Ga.
Although DNA damage is known to be an important mechanism
by which radionuclide decay induces cell killing, it is a currently
open and actively investigated question whether the cell nucleus
and DNA is the most important target for radionuclide emission, or
whether other organelles such as the mitochondria or celltotoxicity of Auger electron-emitting [67Ga]Ga-trastuzumab, Nuclear
7M.F. Othman et al. / Nuclear Medicine and Biology xxx (xxxx) xxxmembrane [49,50] are also important radiosensitive targets. Al-
though not explored here, it is known that [111In]In-trastuzumab
can localise to the nucleus [42,44]. The extent to which this happens
is likely to be an important factor in the therapeutic efficacy of the ra-
diopharmaceutical, considering the very short range of the majority
of its electron emissions. Nuclear localisation peptide sequences
have often been used to further increase therapeutic efficacies of
Auger-emitting radiopharmaceuticals [42–44], including some la-
belled with 67Ga [51]. Although other non-nuclear-associated path-
ways are known that can influence therapeutic efficacy [50], and
despite the longer range of the 67Ga electron emissions, it is possible
that an approach using nuclear localisation sequences will also be of
benefit for [67Ga]Ga-trastuzumab. The data presented here, how-
ever, do not provide insight into the mechanism of cell killing or
sub-cellular target of these radioimmunoconjugates.
Microautoradiography demonstrates a wide range of [67Ga]Ga-
THP-trastuzumab binding among HCC1954 cells, despite the pre-
sumption that the cells are a clonally identical population. In fact,
20% of cells in the highest activity group received around a hundred
times higher radiation dose than the 15% in the lowest activity group,
and a large sub-population of the cells would have received negligi-
ble radiation dose. This may account for the observation (Fig. 3B,
C) that the surviving cell fraction does not greatly diminish below
0.5 as activity of [67Ga]Ga-THP-trastuzumab per cell increases
above 0.05 Bq/cell. It implies that the average activity per cell is likely
to have very limited utility as a predictor of toxicity. Heterogeneity of
target expression is likely to be even greater in cell populations
within patients' tumours. This is likely to be the overriding limitation
in targeted Auger emitter therapy. The impact of non-homogeneous
radiopharmaceutical uptake in limiting anti-tumour effectiveness
will need to be considered for any radiopharmaceutical undergoing
in vitro and in vivo evaluation and requires further investigation if
the antitumour effects of targeted Auger electron-emitting radionu-
clides are to be better understood.7. Conclusion
[67Ga]Ga-THP-trastuzumab specifically reduced cell viability and
clonogenicity of HER2-expressing cells, confirming the potential of
67Ga as a therapeutic radionuclide as part of a targeted radiopharmaceu-
tical. Diminished viability and clonogenicity only occurred when radio-
activity was directly bound to cells and was not caused by radioactivity
in themedium. Highly heterogeneous cellular uptake may compromise
the efficacy of Auger electron irradiation and the interpretation of data
derived from average cellular radioactivity. This merits further investi-
gation using methods, such as microautoradiography, capable of mea-
suring the radioactivity of individual cells.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.nucmedbio.2019.12.004.Acknowledgments
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